EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study

Taeang Arai, Masanori Atsukawa iD, Akihito Tsubota, Tsunekazu Oikawa, Toshifumi Tada, Kentaro Matsuura, Toru Ishikawa, Hiroshi Abe, Keizo Kato, Asahiro Morishita, Joji Tani, Tomomi Okubo und 3 weitere

Diabetes, Obesity and Metabolism · 2024-11 · 26 (11) · 4958-4965

DOI: 10.1111/dom.15898 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 02.09.2024. Verfasst von Taeang Arai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the efficacy and safety of oral semaglutide for type 2 diabetes mellitus (T2DM) in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). Materials and Methods This was a single‐arm, multicentre, prospective study. Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48‐week oral semaglutide treatment as scheduled and were included in an efficacy analysis. Dose adjustments of oral semaglutide were determined by each physician while monitoring efficacy and adverse events.

Results

Significant improvements in body weight, liver enzymes, lipid profile, and glycaemic control were found at 48 weeks compared with baseline values (all p < 0.01). Controlled attenuation parameter values significantly decreased from baseline to 48 weeks ( p < 0.01). Changes in alanine aminotransferase concentrations ( r = 0.37, p < 0.01) and controlled attenuation parameter values ( r = 0.44, p < 0.01) were significantly correlated with changes in body weight. Liver fibrosis markers, such as type IV collagen 7S, Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein, fibrosis‐4 index, and liver stiffness measurement, significantly decreased from baseline to 48 weeks (all p < 0.01). The most common adverse events were Grades 1–2 transient gastrointestinal symptoms, such as nausea (23 patients, 28.8%), dyspepsia (12, 15.0%) and appetite loss (4, 5.0%).

Conclusions

Oral semaglutide treatment for T2DM in patients with MASLD leads to an improvement in liver steatosis and injury, surrogate markers of fibrosis, diabetic status, and lipid profile, and reduces body weight.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsHumansMaleFemaleMiddle AgedProspective StudiesAgedAdministration, OralFatty LiverTreatment OutcomeNon-alcoholic Fatty Liver DiseaseAdultBlood GlucoseGlycated HemoglobinSemaglutide

Stichwörter der Autor:innen

clinical trialdiabetes complicationseffectivenessliver

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsBlood GlucoseGlycated HemoglobinSemaglutide

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo, Japan.
  • Core Research Facilities for Basic Science, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.

ORCID-Profile: Masanori Atsukawa

Zitieren

APA

Arai, T., Atsukawa, M., Tsubota, A., Oikawa, T., Tada, T., Matsuura, K., Ishikawa, T., Abe, H., Kato, K., Morishita, A., Tani, J., Okubo, T., Nagao, M., Iwabu, M., & Iwakiri, K. (2024). Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study. Diabetes, Obesity and Metabolism, 26(11), 4958-4965. https://doi.org/10.1111/dom.15898

Vancouver

Arai T, Atsukawa M, Tsubota A, Oikawa T, Tada T, Matsuura K, et al. Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study. Diabetes, Obesity and Metabolism. 2024;26(11):4958-4965. doi:10.1111/dom.15898

BibTeX
@article{Arai2024,
  author = {Arai, Taeang and Atsukawa, Masanori and Tsubota, Akihito and Oikawa, Tsunekazu and Tada, Toshifumi and Matsuura, Kentaro and Ishikawa, Toru and Abe, Hiroshi and Kato, Keizo and Morishita, Asahiro and Tani, Joji and Okubo, Tomomi and Nagao, Mototsugu and Iwabu, Masato and Iwakiri, Katsuhiko},
  title = {Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {11},
  pages = {4958--4965},
  doi = {10.1111/dom.15898}
}
Kostenlos starten →